Agenus Inc (OQ:AGEN)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 3 Forbes Rd
LEXINGTON MA 02421-7305
Tel: N/A
IR: See website
Key People
Garo H. Armen
Chairman of the Board, Chief Executive Officer, Co-Founder
Jennifer S. Buell
President, Chief Operating Officer
Evan D. Kearns
Chief Compliance Officer, Vice President, General Counsel, Corporate Secretary
Christine M. Klaskin
Vice President - Finance
Steven Oday
Chief Medical Officer
Business Overview
Agenus Inc. (Agenus) is a clinical-stage immuno-oncology (I-O) company. It has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, neoantigen cancer vaccines (individualized and off-the shelf) platforms and adjuvants. Its anti-PD-1 antibody and first-generation and next generation anti-CTLA-4 antagonists are in clinical development. Its pipeline of pre-clinical assets, which include AGEN1777, an anti-TIGIT bispecific antibody and AGEN1327, an anti-TIGIT monospecific antibody. Its neoantigen vaccine platforms include its heat shock protein (HSP) based Prophage vaccine candidates and its synthetic, neoantigen vaccine candidates, AutoSynVax (ASV) and PhosphoSynVax (PSV). Its neoantigen vaccine platforms include individualized ASV and off-the-shelf PSV, which target antigens expressed across patients and tumors.
Financial Overview
For the six months ended 30 June 2021, Agenus Increvenues decreased 47% to $22.4M. Net loss applicable tocommon stockholders increased 49% to $137.1M. Revenuesreflect United States segment decrease of 52% to $19.6M.Higher net loss reflects R & D expenses increase of 10% to$80M (expense), Stock-based Compensation in SGA increasefrom $2.8M to $7.2M (expense).
Employees: 359 as of Feb 28, 2021
Reporting Currency: U.S. Dollars
Enterprise value: $899.31M as of Jun 30, 2021
Annual revenue (TTM): $68.55M as of Jun 30, 2021
EBITDA (TTM): -$158.36M as of Jun 30, 2021
Net annual income (TTM): -$225.94M as of Jun 30, 2021
Free cash flow (TTM): -$169.69M as of Jun 30, 2021
Net Debt Last Fiscal Year: N/A
Shares outstanding: 233,114,645 as of Aug 4, 2021
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.